Targeting specific signaling pathways to treat advanced prostate cancer
RIPK2/MKK7/c-Myc Signaling as a Therapeutic Target in Prostate Cancer Metastasis
['FUNDING_R01'] · STATE UNIVERSITY NEW YORK STONY BROOK · NIH-10896995
This study is looking at how a specific signaling pathway in prostate cancer might help us find new ways to stop the cancer from spreading, so that patients can benefit from better treatments that could slow down or prevent the disease from getting worse.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STATE UNIVERSITY NEW YORK STONY BROOK (nih funded) |
| Locations | 1 site (STONY BROOK, UNITED STATES) |
| Trial ID | NIH-10896995 on ClinicalTrials.gov |
What this research studies
This research investigates the role of RIPK2/MKK7/c-Myc signaling in the metastasis of prostate cancer, aiming to identify new therapeutic targets. By analyzing clinical data, the study focuses on how inhibiting RIPK2 can reduce cancer cell invasion and metastasis. The approach includes both laboratory experiments and in vivo models to assess the effectiveness of potential treatments. Patients may benefit from new therapies that could delay or prevent the spread of prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced or metastatic prostate cancer, particularly those with castration-resistant forms of the disease.
Not a fit: Patients with early-stage prostate cancer or those who do not have metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve survival rates for patients with metastatic prostate cancer.
How similar studies have performed: Previous studies have shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
STONY BROOK, UNITED STATES
- STATE UNIVERSITY NEW YORK STONY BROOK — STONY BROOK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YANG, WEI — STATE UNIVERSITY NEW YORK STONY BROOK
- Study coordinator: YANG, WEI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: androgen independent prostate cancer, androgen indifferent prostate cancer, androgen insensitive prostate cancer, androgen resistance in prostate cancer, androgen resistant prostate cancer